Applied Therapeutics, Inc. (APLT)
| Market Cap | 83.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.11M |
| Shares Out | 26.22M |
| EPS (ttm) | -4.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 347,230 |
| Open | 3.30 |
| Previous Close | 3.40 |
| Day's Range | 3.13 - 3.44 |
| 52-Week Range | 3.13 - 29.80 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 31.83 (+904.1%) |
| Earnings Date | n/a |
About APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for APLT stock is "Buy." The 12-month stock price forecast is 31.83, which is an increase of 904.10% from the latest price.
News
APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Appl...
NEW YORK--(BUSINESS WIRE)-- #Applied--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied The...
APLT INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Applied Therapeutics, Inc. (APLT) Investors t...
SAN FRANCISCO, Jan. 14, 2022 /PRNewswire/ -- Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible...
SHAREHOLDER ALERT: Robbins LLP Investigates Applied Therapeutics, Inc. (APLT) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $APLT #classactioninvestigation--Applied Therapeutics, Inc. (APLT) Holds Submission of New Drug Application for AT-007
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the...
Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations
Boston, Massachusetts--(Newsfile Corp. - January 4, 2022) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Applied Therapeutics, Inc...
Why Applied Therapeutics Stock Is Sliding Today
The company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected.
Why Applied Therapeutics Shares Are Falling Today
Applied Therapeutics (NASDAQ: APLT) is trading significantly lower Monday after the company said it would not immediately submit a new drug application for its AT-007 for treatment of galactosemia. The ...
Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder
Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency...
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Reports Third Quarter 2021 Financial Results
Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters
Applied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why
Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate
Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study. Related Cont...
Applied Therapeutics Reports Second Quarter 2021 Financial Results
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing
Applied Therapeutics Added to Russell Microcap® Index
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientif...
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart's ability to function People with diabetes or pre-diabetes who have D...
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions ...
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder
The FDA has granted Fast Track designation to Applied Therapeutics Inc's (NASDAQ: APLT) AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is the Company's central nervous system-penetrant A...
Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecula...
Applied Therapeutics Reports First Quarter 2021 Financial Results
Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency
Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA